Angiotensin II receptor antagonists: Difference between revisions
No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| (4 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Also known as angiotensin receptor blockers (ARBs), AT<sub>1</sub>-receptor antagonists or sartans | *Also known as angiotensin receptor blockers (ARBs), AT<sub>1</sub>-receptor antagonists or sartans | ||
*A group of pharmaceuticals that modulate the | *A group of pharmaceuticals that modulate the renin–angiotensin system, they block activation of angiotensin II AT<sub>1</sub> receptors, thus preventing angiotensin II from binding | ||
*Main uses are in the treatment of [[hypertension]], diabetic nephropathy and [[congestive heart failure]] | *Main uses are in the treatment of [[hypertension]], diabetic nephropathy and [[congestive heart failure]] | ||
==Medications== | |||
{| class="wikitable" | |||
|+ | |||
|- | |||
! Drug | |||
! Trade Name | |||
! Biological half-life [h] | |||
! Protein binding [%] | |||
! Bioavailability [%] | |||
! Renal/hepatic clearance [%] | |||
! Food effect | |||
! Daily dosage [mg] | |||
|- | |||
| [[Losartan]] | |||
| Cozaar | |||
| 6-9 h | |||
| 98.7% | |||
| 33% | |||
| 10%/90% | |||
| Minimal | |||
| 50–100 mg | |||
|- | |||
| EXP 3174 | |||
| | |||
| 6–9 h | |||
| 99.8% | |||
| – | |||
| 50%/50% | |||
| – | |||
| – | |||
|- | |||
| [[Candesartan]] | |||
| Atacand | |||
| 9h | |||
| >99% | |||
| 15% | |||
| 60%/40% | |||
| No | |||
| 4–32 mg | |||
|- | |||
| [[Valsartan]] | |||
| Diovan | |||
| 6 h | |||
| 95% | |||
| 25% | |||
| 30%/70% | |||
| No | |||
| 80–320 mg | |||
|- | |||
| [[Irbesartan]] | |||
| Avapro | |||
| 11–15 h | |||
| 90–95% | |||
| 70% | |||
| 1%/99% | |||
| No | |||
| 150–300 mg | |||
|- | |||
| [[Telmisartan]] | |||
| Micardis | |||
| 24 h | |||
| >99% | |||
| 42–58% | |||
| 1%/99% | |||
| No | |||
| 40–80 mg | |||
|- | |||
| [[Eprosartan]] | |||
| Teveten | |||
| 5 h | |||
| 98% | |||
| 13% | |||
| 30%/70% | |||
| No | |||
| 400–800 mg | |||
|- | |||
| [[Olmesartan]] | |||
| Benicar/Olmetec | |||
| 14–16 h | |||
| >99% | |||
| 29% | |||
| 40%/60% | |||
| No | |||
| 10–40 mg | |||
|- | |||
| [[Azilsartan]] | |||
| Edarbi | |||
| 11 h | |||
| >99% | |||
| 60% | |||
| 55%/42% | |||
| No | |||
| 40–80 mg | |||
|- | |||
| [[Fimasartan]] | |||
| Kanarb | |||
| 7-11 h | |||
| >97% | |||
| 30-40% | |||
| - | |||
| - | |||
| 30–120 mg | |||
|} | |||
==See Also== | ==See Also== | ||
*[[Antihypertensive medications]] | *[[Antihypertensive medications]] | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:Cardiology]] | ||
Revision as of 17:12, 19 September 2019
Background
- Also known as angiotensin receptor blockers (ARBs), AT1-receptor antagonists or sartans
- A group of pharmaceuticals that modulate the renin–angiotensin system, they block activation of angiotensin II AT1 receptors, thus preventing angiotensin II from binding
- Main uses are in the treatment of hypertension, diabetic nephropathy and congestive heart failure
Medications
| Drug | Trade Name | Biological half-life [h] | Protein binding [%] | Bioavailability [%] | Renal/hepatic clearance [%] | Food effect | Daily dosage [mg] |
|---|---|---|---|---|---|---|---|
| Losartan | Cozaar | 6-9 h | 98.7% | 33% | 10%/90% | Minimal | 50–100 mg |
| EXP 3174 | 6–9 h | 99.8% | – | 50%/50% | – | – | |
| Candesartan | Atacand | 9h | >99% | 15% | 60%/40% | No | 4–32 mg |
| Valsartan | Diovan | 6 h | 95% | 25% | 30%/70% | No | 80–320 mg |
| Irbesartan | Avapro | 11–15 h | 90–95% | 70% | 1%/99% | No | 150–300 mg |
| Telmisartan | Micardis | 24 h | >99% | 42–58% | 1%/99% | No | 40–80 mg |
| Eprosartan | Teveten | 5 h | 98% | 13% | 30%/70% | No | 400–800 mg |
| Olmesartan | Benicar/Olmetec | 14–16 h | >99% | 29% | 40%/60% | No | 10–40 mg |
| Azilsartan | Edarbi | 11 h | >99% | 60% | 55%/42% | No | 40–80 mg |
| Fimasartan | Kanarb | 7-11 h | >97% | 30-40% | - | - | 30–120 mg |